Brokerages Set Coya Therapeutics, Inc. (NASDAQ:COYA) PT at $16.00

Coya Therapeutics, Inc. (NASDAQ:COYA) has received a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $16.00.

Several analysts recently weighed in on COYA shares. Wall Street Zen downgraded Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. Chardan Capital restated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Monday, March 16th. D. Boral Capital reaffirmed a “buy” rating and issued a $15.00 price target on shares of Coya Therapeutics in a research report on Monday, March 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday.

Institutional Trading of Coya Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Prosperity Wealth Management Inc. lifted its stake in shares of Coya Therapeutics by 16.4% during the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after purchasing an additional 3,350 shares during the last quarter. Cetera Investment Advisers bought a new position in Coya Therapeutics in the fourth quarter worth about $128,000. Millennium Management LLC purchased a new stake in shares of Coya Therapeutics during the fourth quarter valued at about $121,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Coya Therapeutics in the 2nd quarter valued at about $119,000. Finally, Occudo Quantitative Strategies LP purchased a new position in shares of Coya Therapeutics in the 4th quarter worth approximately $66,000. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Stock Down 0.5%

Shares of NASDAQ:COYA opened at $4.18 on Tuesday. The business’s 50 day moving average is $4.66 and its 200 day moving average is $5.46. The stock has a market cap of $98.06 million, a P/E ratio of -3.29 and a beta of 0.23. Coya Therapeutics has a 52-week low of $3.94 and a 52-week high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Monday, March 16th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26). Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. The firm had revenue of $3.96 million for the quarter, compared to the consensus estimate of $1.93 million. On average, sell-side analysts anticipate that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.